Canaccord Genuity Reiterates a 'Buy' on Immunogen (IMGN); Strong 2012 Catalyst Lineup

Canaccord Genuity reiterates a 'Buy' on Immunogen Inc. (NASDAQ: IMGN) price target of $17.00.

Analyst, George Farmer, said, "With several 2012 clinical and regulatory catalysts that we expect to support continued stock momentum, we reiterate our rating on IMGN...IMGN reported December-end cash was $168M. We estimate June F2012-end cash of $152M as sufficient into late 2014."

For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.

Shares of Immunogen Inc. closed at $13.83 yesterday, with a 52 week range of $8.06-$16.20.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains
• Nomura Securities Maintains a 'Neutral' on Urban Outfitters (URBN); Staying Sidelined Despite Positive Q1 Surprises
• Compass Point Reiterates a 'Sell' on Post Properties (PPS); Adjusting Numbers

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Genuity Capital Markets

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter